ClinicalTrials.gg
CompletedNCT00345319Updated Dec 14, 2011

Purified Rabies Vaccine for Human Use (Chick-embryo Cell)

A Phase 3 interventional study of rabies vaccine in Rabies Post-exposure Prophylaxis, sponsored by Novartis Vaccines. Completed at 1 site in China. Open to participants aged 10 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-12-14.

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
630
Allocation
Randomized
Ages
10 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Rabies with a site in China — 5 open to participants now, 9 under way, 4 of them phase 3. Rabies · China.

Enrollment
19th of 32
630 · median 821
Started
2006
the only one that year
Phase 3
18 of 35
1 open now
Registered
1st of 35
by date
Lead sponsor
4 of 35
Novartis Vaccines

Among the 35 studies in Rabies with a site in China, this one is the 19th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2006, is one of 18 in phase 3, and was the 1st registered.

Rabies

115 studies on the registry are indexed under Rabies; 12 are open to participants now.

Browse Rabies studies →

Open to participants now

5 of the 35 studies in Rabies with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2 Rabies studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 10 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Rabies with a site in China, or all of them as a file.
02

Study summary

Evaluate the immunogenicity and safety of rabies vaccine given in a post-exposure prophylaxis regimen to healthy children and adults aged 10-60 years.

03

Conditions studied

  • Rabies Post-exposure Prophylaxis

Browse trials for

Keywords

  • rabies
  • vaccine
  • post-exposure prophylaxis
04

Who can participate

Ages eligible
10 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male and female healthy subjects aged 10-60 years old

Exclusion criteria

Exclusion Criteria:

  • history of rabies immunization
  • previous exposure to a suspect rabid animal within the last 12 months
  • any significant acute or chronic infections requiring systemic antibiotic treatment or antiviral therapy within the past 7 days
  • treatment with , or anti-malaria drugs during the two month period before enrollment
  • known/suspected immunodeficiency, or disease, or any immunologic disorder
  • known to neomycin, tetracycline, amphotericin-B, or any other vaccine component
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
630 participants (actual)

Study arms

  • Active comparator
    Group 1

    Biological: rabies vaccine

  • Active comparator
    Group 2

    Biological: rabies vaccine

Interventions

  • Biologicalrabies vaccine

    Administration of PCECV according to ESSEN regimen

06

What researchers measure

Primary outcomes

  1. serum bactericidal activity

    Time frame: measured at day 14 and day 45 after first vaccination dose

Secondary outcomes

  1. solicited local and systemic reactions

    Time frame: within 6 days following vaccination and adverse events thought the study

07

Study locations

1 site
  • Danyang CDC
    Danyang, Jiangsu, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of May 2006 and a completion of May 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2006
First posted
Jun 28, 2006
Start
Mar 2006
Primary completionActual
May 2006
CompletionActual
May 2006
Last update
Dec 14, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00345319
Lead sponsor
Novartis Vaccines
Responsible party
Sponsor
First posted
Jun 28, 2006
Start date
Mar 2006
Primary completion
May 2006
Completion
May 2006
Last update
Dec 14, 2011

Study contacts

Novartis Vaccines - Information Services
study chair · Novartis Vaccines & Diagnostics
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion